New York, January 17, 2026, 14:48 (EST) — Market closed.
- PM shares ended Friday 0.6% higher, closing at $173.62 following a new U.S. investment update
- Since 2022, PMI has flagged over $20 billion in U.S.-related investments, mostly linked to Swedish Match and subsequent expenditures
- Next up: Tuesday’s reopening post-holiday and the PMI results due Feb. 6
Philip Morris International (PM.N) shares edged up 0.6% on Friday, finishing at $173.62. The stock fluctuated between $170.76 and $174.24 during the session, with roughly 5.1 million shares traded.
The stock’s movement reflects ongoing debate over how much of Philip Morris’ growth hinges on the U.S. market and the pace at which smokers will switch to smoke-free nicotine products.
That’s the real driver behind valuation, not catchy slogans. In the U.S., regulators control which new nicotine products hit shelves and set the rules around their marketing. Meanwhile, cigarette sales continue to decline across multiple markets.
In a Jan. 15 press release, PMI announced it has poured over $20 billion into U.S.-related investments since 2022. That includes roughly $19 billion last year linked to the Swedish Match acquisition, plus more than $1 billion earmarked through Sept. 30, 2025. Infrastructure projects in Colorado, Kentucky, and North Carolina are projected to generate over 1,000 direct jobs and 1,500 indirect ones. PMI U.S. CEO Stacey Kennedy said, “We’re investing in the country’s future, starting with accelerating the shift to a smoke-free America.” SEC
The disclosure appeared in a Form 8-K filing under Regulation FD, mandating wide public distribution of material info. The document specifies the release was “furnished,” not “filed,” which reduces liability under SEC regulations. SEC
PMI’s U.S. growth strategy hinges on nicotine pouches and heated tobacco, both tightly controlled by FDA marketing approvals. Last year, the FDA greenlit marketing for 20 ZYN nicotine pouch products under the PMTA process, the premarket review that determines if new tobacco products can hit the U.S. market. U.S. Food and Drug Administration
Other tobacco stocks edged up slightly on Friday, with Altria adding 0.3% and British American Tobacco up 0.2%.
Wall Street wrapped up Friday nearly flat ahead of the long weekend, with the three major U.S. indexes all posting losses for the week as fourth-quarter earnings season kicked off. Reuters
U.S. equity markets will be closed Monday, Jan. 19, in observance of Martin Luther King Jr. Day and will resume trading Tuesday. New York Stock Exchange
But the upside isn’t guaranteed. FDA reviews often stall, marketing regulations might tighten, and sudden shifts like excise taxes or lawsuits can hit demand quicker than any factory expansion can respond.
PMI is set to release its 2025 fourth-quarter and full-year results on Feb. 6 at 9 a.m. EST, per its investor relations calendar. Investors will focus on any updates regarding U.S. spending and the regulatory schedule for upcoming smoke-free product launches. pmi.com
